{
  "questions": [
    {
      "type": "factoid",
      "id": "63f57d9b33942b094c000004",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "tryptophan",
          1.9998141988791285
        ],
        [
          "try",
          0.00014740811175844993
        ],
        [
          "tryptophan absorption",
          6.254229261155984e-06
        ],
        [
          "tryptophan absorption was postulated as the underlying pathology",
          6.1141194517797014e-06
        ],
        [
          "a new metabolic disease which is deficient in the transport of tryptophan",
          1.6961983119879204e-06
        ],
        [
          "deficient in the transport of tryptophan",
          7.333975018709903e-07
        ],
        [
          "An intestinal defect of tryptophan",
          6.013206647320839e-07
        ],
        [
          "nephrocalcinosis. An intestinal defect of tryptophan",
          5.104515263034505e-07
        ],
        [
          "trypt",
          3.716371765792971e-07
        ],
        [
          "tryptop",
          3.3589614112266584e-07
        ],
        [
          "new metabolic disease which is deficient in the transport of tryptophan",
          2.6176179633022245e-07
        ],
        [
          "hypercalcemia, and nephrocalcinosis. An intestinal defect of tryptophan",
          1.5790543909669703e-07
        ],
        [
          "intestinal defect of tryptophan",
          1.378264461474086e-07
        ],
        [
          "which is deficient in the transport of tryptophan",
          1.275521948611041e-07
        ],
        [
          "metabolic disease which is deficient in the transport of tryptophan",
          1.0462042266108946e-07
        ],
        [
          "in a new metabolic disease which is deficient in the transport of tryptophan",
          1.0398441002716296e-07
        ],
        [
          "a new metabolic disease which is deficient in the transport of try",
          2.0048735589237615e-10
        ],
        [
          "deficient in the transport of try",
          8.669530185232598e-11
        ],
        [
          "An intestinal defect of try",
          1.757550042448395e-11
        ],
        [
          "nephrocalcinosis. An intestinal defect of try",
          1.4919562129503676e-11
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6450ec0c57b1c7a31500008f",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "frataxin",
          0.5146545233398306
        ],
        [
          "FXN gene, which leads to decreased levels of the frataxin",
          0.4526309724261659
        ],
        [
          "frataxin protein",
          0.010866153189266915
        ],
        [
          "FXN gene, which leads to decreased levels of the frataxin protein",
          0.009556619560384075
        ],
        [
          "FXN gene",
          0.009122867342024669
        ],
        [
          "a triplet guanine-adenine-adenine (GAA) repeat expansion",
          0.0009002502607932552
        ],
        [
          "FXN",
          0.0006708603172859435
        ],
        [
          "expansion in intron 1 of the FXN gene, which leads to decreased levels of the frataxin",
          0.0001648050987913186
        ],
        [
          "which leads to decreased levels of the frataxin",
          0.00013728114470479088
        ],
        [
          "the FXN gene, which leads to decreased levels of the frataxin",
          0.00012831729505328326
        ],
        [
          "guanine-adenine-adenine (GAA) repeat expansion",
          5.9759562428360844e-05
        ],
        [
          "FRDA",
          5.9403931409329736e-05
        ],
        [
          "a triplet guanine-adenine-adenine (GAA) repeat expansion in intron 1 of the FXN gene",
          5.920435665199348e-05
        ],
        [
          "decreased levels of the frataxin",
          4.66497750363353e-05
        ],
        [
          "leads to decreased levels of the frataxin",
          4.384048391858559e-05
        ],
        [
          "expansion",
          4.1350186894339986e-05
        ],
        [
          "the frataxin",
          3.4268709037758077e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644ef46557b1c7a315000083",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Oncogenes",
          0.9699247399346319
        ],
        [
          "Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes",
          0.025184260054214102
        ],
        [
          "Oncogenes are gain-of-function mutations of normal regulatory genes",
          0.0027350771774995643
        ],
        [
          "Oncogene",
          0.0018463761029638983
        ],
        [
          "On",
          0.00022045257388718796
        ],
        [
          "Proto-oncogenes are altered by point mutation, amplification or rearrangement",
          3.384107740589707e-05
        ],
        [
          "oncogenes are believed to be important contributors to human carcinogenesis",
          3.1695526651186834e-05
        ],
        [
          "Proto-oncogenes",
          1.2558547955973175e-05
        ],
        [
          "oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes",
          6.519209534728589e-06
        ],
        [
          "gain-of-function mutations of normal regulatory genes or proto-oncogenes",
          2.0843298827395265e-06
        ],
        [
          "Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes",
          1.1225467680053559e-06
        ],
        [
          "retroviruses initiating a variety of animal and avian cancers, oncogenes",
          9.683794252660015e-07
        ],
        [
          "normal regulatory genes or proto-oncogenes",
          3.045391796211238e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6432fdd857b1c7a315000020",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "autosomal dominant",
          0.9979271306585129
        ],
        [
          "Hereditary angioedema (HAE) is a rare autosomal dominant",
          0.0012244211913676015
        ],
        [
          "dominant",
          0.0006736230681012329
        ],
        [
          "auto",
          0.00010134376335226051
        ],
        [
          "autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes",
          5.309658347792696e-05
        ],
        [
          "autosomal",
          7.244770550599575e-06
        ],
        [
          "rare autosomal dominant",
          2.491074110812992e-06
        ],
        [
          "autosomal dominant disorder caused by mutations of the SERPING1",
          2.193593442268881e-06
        ],
        [
          "a rare autosomal dominant",
          1.839101672866338e-06
        ],
        [
          "autoso",
          1.4540106955153146e-06
        ],
        [
          "autosomal dominant disorder caused by mutations of the SERPING1 or the Factor 12",
          9.402613931942962e-07
        ],
        [
          "(HAE) is a rare autosomal dominant",
          8.346424764110486e-07
        ],
        [
          "autosomal dominant disorder",
          6.439826327815564e-07
        ],
        [
          "angioedema (HAE) is a rare autosomal dominant",
          5.867080526707719e-07
        ],
        [
          "autosomal dominant disorder caused by mutations of",
          1.5021100096280342e-07
        ],
        [
          "Hereditary angioedema (HAE) is a rare auto",
          1.2434520282013797e-07
        ],
        [
          "autosomal dominant disorder caused",
          1.0830761992058815e-07
        ],
        [
          "dominant disorder caused by mutations of the SERPING1 or the Factor 12 genes",
          3.328762874317927e-08
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6450ede757b1c7a315000090",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "first or second decade",
          0.9742301295517647
        ],
        [
          "second decade",
          0.01398023589070641
        ],
        [
          "the first or second decade",
          0.0051630937250256
        ],
        [
          "Friedreich's ataxia is classically considered a disease with onset in the first or second decade",
          0.004429229715531754
        ],
        [
          "decade",
          0.001400287416179926
        ],
        [
          "first",
          0.00040455467271229543
        ],
        [
          "in the first or second decade",
          0.0002854652938650688
        ],
        [
          "first or second",
          6.285462813803061e-05
        ],
        [
          "or second decade",
          2.0578443253052127e-05
        ],
        [
          "onset in the first or second decade",
          8.451652599536147e-06
        ],
        [
          "classically considered a disease with onset in the first or second decade",
          5.4950917786038605e-06
        ],
        [
          "a disease with onset in the first or second decade",
          2.7118546018103054e-06
        ],
        [
          "with onset in the first or second decade",
          2.4012643505807663e-06
        ],
        [
          "disease with onset in the first or second decade",
          2.3667950847468907e-06
        ],
        [
          "the first",
          2.1440044079437947e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63f03d58f36125a42600001f",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "hip fracture",
          1.0407410564840427
        ],
        [
          "fracture",
          1.0026574668855301
        ],
        [
          "hip fractures",
          0.9210564373371571
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI - An Abridged Protocol",
          0.6347742937491361
        ],
        [
          "Hemiarthroplasty",
          0.08446778376942407
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI",
          0.07896909184058824
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation",
          0.06288056230801604
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre",
          0.02960382340468121
        ],
        [
          "displaced intracapsular hip fractures",
          0.028181461701359996
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation -",
          0.02486048402309141
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3",
          0.024791622510305252
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE 3: HEMI -",
          0.023841938578945916
        ],
        [
          "Hemiarthroplasty Evaluation",
          0.016635024705548968
        ],
        [
          "Hemiarthroplasty Evaluation by Multicentre Investigation - WHITE",
          0.014245628722418214
        ],
        [
          "fractures",
          0.0039898794248635645
        ],
        [
          "displaced intracapsular hip fracture",
          0.0013398274950729447
        ],
        [
          "intracapsular hip fractures",
          0.0011475982890484415
        ],
        [
          "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty",
          0.001066541963073152
        ],
        [
          "The World Hip Trauma Evaluation Study 3: Hemiarthroplasty Evaluation by Multicentre Investigation",
          0.0007939684856205662
        ],
        [
          "HEMI - An Abridged Protocol",
          0.0007570434219072993
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644008a657b1c7a31500003f",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Omaveloxolone",
          0.9999075531690063
        ],
        [
          "Omaveloxolo",
          5.3580373024785064e-05
        ],
        [
          "O",
          3.5818340975704345e-05
        ],
        [
          "Omaveloxolone (RTA 408) is an activator of Nrf2 and an inhibitor of NF\u03baB",
          1.0764164425799147e-06
        ],
        [
          "Omavelox",
          9.140481577234004e-07
        ],
        [
          "Omaveloxolone (RTA 408) is an activator of Nrf2",
          5.34171093120416e-07
        ],
        [
          "Oma",
          1.4588266517524483e-07
        ],
        [
          "Omaveloxolone (RTA 408)",
          9.997485699076408e-08
        ],
        [
          "Omavel",
          4.6110716965384133e-08
        ],
        [
          "Omaveloxolone (RTA 408) is an activator",
          2.198922530183155e-08
        ],
        [
          "Nrf2 and an inhibitor of NF\u03baB",
          1.2481252453110793e-11
        ],
        [
          "Nrf2",
          6.193814961067069e-12
        ],
        [
          "NF\u03baB, possessing antioxidative and anti-inflammatory activities in mitochondrial bioenergetics",
          3.3502862736639273e-12
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644640de57b1c7a31500006b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "loss of the SMN1 gene in most cases or mutations in rare cases",
          0.7717090851284137
        ],
        [
          "Loss or deletion of survival motor neuron 1 gene (SMN1)",
          0.6683371649785879
        ],
        [
          "defects in the survival motor neuron 1 (SMN1) gene",
          0.6149523531507624
        ],
        [
          "mutations in SMN1 (encoding survival motor neuron protein (SMN))",
          0.39514281878916824
        ],
        [
          "Loss or deletion of survival motor neuron 1 gene",
          0.31703232273255283
        ],
        [
          "mutations",
          0.24756300192704134
        ],
        [
          "mutations in SMN1",
          0.2139520871177035
        ],
        [
          "defects in the survival motor neuron 1 (SMN1)",
          0.11983755012570607
        ],
        [
          "defects in the survival motor neuron 1",
          0.08495303634438413
        ],
        [
          "survival motor neuron 1 (SMN1) gene",
          0.0704226428758722
        ],
        [
          "loss of the SMN1 gene",
          0.06506213695497827
        ],
        [
          "SMN1 gene in most cases or mutations in rare cases",
          0.05728379466138542
        ],
        [
          "loss of the SMN1",
          0.03896916593291296
        ],
        [
          "survival motor neuron 1 (SMN1)",
          0.013723464838182433
        ],
        [
          "loss",
          0.013049336553825622
        ],
        [
          "defects",
          0.011025095832434257
        ],
        [
          "survival motor neuron 1",
          0.009728586790584817
        ],
        [
          "SMN1",
          0.009669117202233906
        ],
        [
          "SMN1) gene",
          0.009054186831292166
        ],
        [
          "mutations in",
          0.00892289286943053
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64403a5857b1c7a31500004c",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "phase III trial with two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
          0.8492575735402599
        ],
        [
          "phase III trial with two suprachoroidal injections",
          0.06082272099419118
        ],
        [
          "phase III trial with two suprachoroidal injections of CLS-TA",
          0.01920990581473652
        ],
        [
          "phase III",
          0.011445189101971414
        ],
        [
          "suprachoroidal injections of CLS-TA at 0 and 12 weeks",
          0.007171950844269921
        ],
        [
          "phase",
          0.005048108628026238
        ],
        [
          "phase III trial with two",
          0.0030369856186455847
        ],
        [
          "phase III trial with two suprachoroidal",
          0.002550556522601136
        ],
        [
          "phase III trial with two suprachoroidal injection",
          0.001891322854374502
        ],
        [
          "phase III trial with two suprachoroidal injections of CLS-TA at",
          0.0017248072905169602
        ],
        [
          "two suprachoroidal injections of CLS-TA at 0 and 12 weeks",
          0.0010894713475472207
        ],
        [
          "suprachoroidal injections",
          0.0005136457757646409
        ],
        [
          "12 weeks",
          0.0004120485272324537
        ],
        [
          "CLS-TA at 0 and 12 weeks",
          0.00040777130872535433
        ],
        [
          "NCT02595398",
          0.00023116972695779302
        ],
        [
          "suprachoroidal injections of CLS-TA at 0 and 12 weeks with follow up lasting 24 weeks",
          0.00017909350676443344
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64402bb057b1c7a315000043",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "phase I/II",
          0.6726272815274289
        ],
        [
          "Randomized",
          0.5667570057735866
        ],
        [
          "Randomized, clinical trial",
          0.37596735182166
        ],
        [
          "phase I/II double-blind, comparator-controlled trial",
          0.25846917769281125
        ],
        [
          "Random",
          0.05214513726732886
        ],
        [
          "phase",
          0.018743518710994857
        ],
        [
          "phase I/II double-blind",
          0.012677913099949078
        ],
        [
          "phase I/II double-blind, comparator-controlled",
          0.01250274758237464
        ],
        [
          "double-blind, comparator-controlled trial",
          0.01141903177536606
        ],
        [
          "phase I",
          0.0062995627729835815
        ],
        [
          "Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia",
          0.003089167152123121
        ],
        [
          "We conducted a phase I/II",
          0.0018474335725945368
        ],
        [
          "Randomized, clinical trial of RT001:",
          0.0015556155914422597
        ],
        [
          "phase I/II double-blind, comparator-controlled trial with 2 doses",
          0.001543369432335073
        ],
        [
          "phase I/II double",
          0.0013016245345790966
        ],
        [
          "We conducted a phase I/II double-blind, comparator-controlled trial",
          0.0007099097070018718
        ],
        [
          "double-blind",
          0.0005601035056710151
        ],
        [
          "double-blind, comparator-controlled",
          0.0005523647856078122
        ],
        [
          "phase I/II double-blind, comparator",
          0.0004975507342203445
        ],
        [
          "Randomized, clinical trial of RT001: Early signals of efficacy",
          0.00013517671415770154
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63eef8d6f36125a42600000f",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "malaria",
          1.9964050628912087
        ],
        [
          "antimalarial",
          0.685250474380027
        ],
        [
          "antimalaria",
          0.3055166955638445
        ],
        [
          "L9LS, a potent and safe antimalaria",
          0.008657295219720454
        ],
        [
          "antimalarial monoclonal antibody, and its protective efficacy against controlled human malaria",
          0.003530458907710066
        ],
        [
          "a potent and safe antimalaria",
          0.0002069460603994781
        ],
        [
          "potent and safe antimalaria",
          7.195162270261475e-05
        ],
        [
          "L9LS, a potent and safe antimalarial",
          5.271791669246411e-05
        ],
        [
          "antimalarial monoclonal antibody",
          4.2512971120684135e-05
        ],
        [
          "antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection",
          1.5950940969013223e-05
        ],
        [
          "malaria infection in healthy adults who had never had malaria or received a vaccine for malaria",
          9.82329093760841e-06
        ],
        [
          "malaria after controlled infection, without evident safety concerns",
          7.77493486073778e-06
        ],
        [
          "L9LS administered intravenously or subcutaneously protected recipients against malaria",
          6.555176703716629e-06
        ],
        [
          "malaria after controlled infection",
          3.721045132197072e-06
        ],
        [
          "human malaria",
          2.769423279862059e-06
        ],
        [
          "monoclonal antibody, and its protective efficacy against controlled human malaria",
          1.935509956847133e-06
        ],
        [
          "antimal",
          1.7373673477769396e-06
        ],
        [
          "a potent and safe antimalarial",
          1.2601817190110342e-06
        ],
        [
          "antimalarial monoclonal antibody, demonstrated 88%",
          8.556336680931922e-07
        ],
        [
          "malaria infection",
          7.354901978886475e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64121f44201352f04a000037",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "proteolysis targeting chimeras",
          0.9996601447141933
        ],
        [
          "proteolysis targeting chimera",
          0.9988042858157089
        ],
        [
          "chimera",
          0.0007778371234686138
        ],
        [
          "The emerging technology proteolysis targeting chimera",
          0.00033082165289966133
        ],
        [
          "chimeras",
          0.00014160122747307655
        ],
        [
          "Design and synthesis of proteolysis targeting chimeras",
          0.00012900742439704246
        ],
        [
          "proteolysis targeting chimera (PROTAC) could be an alternative strategy to overcome these problems",
          4.342891043512172e-05
        ],
        [
          "proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686",
          3.158413541548174e-05
        ],
        [
          "proteolysis targeting ch",
          2.99228353612269e-05
        ],
        [
          "proteolysis targeting chimeras (PROTACs) as an EGFR degrader",
          1.069198417463486e-05
        ],
        [
          "proteolysis targeting chimeras (PROTACs)",
          6.6255847944801705e-06
        ],
        [
          "targeting chimeras",
          6.3753944219832096e-06
        ],
        [
          "emerging technology proteolysis targeting chimera",
          6.2690745828824975e-06
        ],
        [
          "pro",
          4.993687859808309e-06
        ],
        [
          "proteolysis targeting chimera (PROTAC)",
          3.7654699005922474e-06
        ],
        [
          "proteolysis targeting chime",
          2.9592929726789402e-06
        ],
        [
          "targeting chimera",
          2.193930839830322e-06
        ],
        [
          "proteolysis targeting",
          1.26323148696478e-06
        ],
        [
          "of proteolysis targeting chimeras",
          1.170005591560961e-06
        ],
        [
          "technology proteolysis targeting chimera",
          7.268734665419563e-07
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6451029f57b1c7a315000094",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "1:40,000",
          0.8967703439918314
        ],
        [
          "1:40,000 - 1:77,000 liveborn infants a year",
          0.07112379467206092
        ],
        [
          "1:40,000 - 1:77,000 liveborn infants",
          0.016777832387009344
        ],
        [
          "1:40,000 - 1:77,000",
          0.010162011799081452
        ],
        [
          "1",
          0.0027802665864537063
        ],
        [
          "1:",
          0.0008906275595825725
        ],
        [
          "40,000",
          0.0007745567216750277
        ],
        [
          "50% of cases in this age group. Its estimated incidence is 1:40,000",
          0.00030941833488689214
        ],
        [
          "1:77,000 liveborn infants a year",
          0.00010762414773571733
        ],
        [
          "more than 50% of cases in this age group. Its estimated incidence is 1:40,000",
          8.638261505974357e-05
        ],
        [
          "Its estimated incidence is 1:40,000",
          7.387236831306412e-05
        ],
        [
          "40,000 - 1:77,000 liveborn infants a year",
          6.143090435959055e-05
        ],
        [
          "1:77,000 liveborn infants",
          2.538812671385653e-05
        ],
        [
          "1:77,000",
          1.5377102194830826e-05
        ],
        [
          "40,000 - 1:77,000 liveborn infants",
          1.4491316464199934e-05
        ],
        [
          "40,000 - 1:77,000",
          8.777112888995331e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6432f5f257b1c7a31500001c",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "BTK",
          1.8885297512623733
        ],
        [
          "BTK inhibitor",
          0.07632128435818422
        ],
        [
          "BTK inhibitor, has been approved for treating adults with mantle cell lymphoma",
          0.011832331909087751
        ],
        [
          "BT",
          0.01106736278345384
        ],
        [
          "BTK inhibitor, was designed to block BTK more specifically than ibrutinib",
          0.0005693430160642129
        ],
        [
          "BTK inhibitor, was designed to block BTK",
          9.522100615595494e-05
        ],
        [
          "CD20-based therapy. B",
          2.3438049911687184e-05
        ],
        [
          "zanubrutinib, a next-generation BTK",
          2.1996234836806238e-05
        ],
        [
          "In the United States, zanubrutinib, a next-generation BTK",
          2.1543806669345698e-05
        ],
        [
          "next-generation BTK",
          1.9980780068251088e-05
        ],
        [
          "BTK inhibitor, was designed to block BTK more specifically",
          1.9339823724135673e-05
        ],
        [
          "CD20",
          1.806283514779935e-05
        ],
        [
          "a next-generation BTK",
          1.531243794801792e-05
        ],
        [
          "To reduce these side effects, zanubrutinib, a next-generation BTK",
          1.3430394940843604e-05
        ],
        [
          "B",
          8.689493180143516e-06
        ],
        [
          "CD20-based therapy",
          2.975902405063547e-06
        ],
        [
          "In the United States, zanubrutinib, a next-generation BTK inhibitor",
          1.5909307531447486e-06
        ],
        [
          "zanubrutinib, a next-generation BTK inhibitor",
          1.5271048598294971e-06
        ],
        [
          "next-generation BTK inhibitor",
          1.4238336946488288e-06
        ],
        [
          "anti-CD20-based therapy. B",
          1.313242876468983e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6440420857b1c7a315000050",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "cabotegravir ER injectable suspension",
          0.9324445519976335
        ],
        [
          "HIV-1 pre-exposure prophylaxis",
          0.80348071174679
        ],
        [
          "Cabotegravir Extended-Release Injectable Suspension",
          0.8000773871097517
        ],
        [
          "PrEP",
          0.6111548449572197
        ],
        [
          "Cabotegravir ER injectable suspension is indicated in the USA for PrEP",
          0.3795211790108948
        ],
        [
          "Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis",
          0.1289613359008379
        ],
        [
          "approved for HIV-1 pre-exposure prophylaxis",
          0.07060141416397435
        ],
        [
          "cabotegravir",
          0.046562501655978056
        ],
        [
          "pre-exposure prophylaxis",
          0.03805103151224193
        ],
        [
          "for HIV-1 pre-exposure prophylaxis",
          0.03688501129033008
        ],
        [
          "Cabotegravir Extended-Release Injectable Suspension: A Review",
          0.017072271220764334
        ],
        [
          "HIV-1 pre-exposure prophylaxis (PrEP)",
          0.017015836220704444
        ],
        [
          "injectable suspension",
          0.011701476929569321
        ],
        [
          "Cabotegravir Extended-Release Injectable Suspension:",
          0.010596219710963882
        ],
        [
          "intramuscular administration, cabotegravir ER injectable suspension",
          0.0074974430842699325
        ],
        [
          "suspension",
          0.006779481401425504
        ],
        [
          "the first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
          0.006452475299220216
        ],
        [
          "first long-acting injectable option to be approved for HIV-1 pre-exposure prophylaxis",
          0.00632086530809306
        ],
        [
          "Cabotegravir Extended-Release",
          0.005569588802873384
        ],
        [
          "Cabotegravir extended-release (ER) injectable suspension",
          0.004760739047813024
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63eef4f5f36125a42600000b",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "multiple sclerosis",
          4.0069750918447244
        ],
        [
          "MS",
          0.9999240337638172
        ],
        [
          "Relapsing Multiple Sclerosis",
          0.9916853509713597
        ],
        [
          "CD20",
          0.5521682607924706
        ],
        [
          "CD20 therapy about to be approved",
          0.38771752148077193
        ],
        [
          "pathogenic cell populations",
          0.19650418599343744
        ],
        [
          "CD52 monoclonal antibody alemtuzumab and the anti-CD20",
          0.1357267590533775
        ],
        [
          "CD52",
          0.0838234672781575
        ],
        [
          "CD20 therapy",
          0.06991488602320392
        ],
        [
          "anti-CD20",
          0.05034707776251449
        ],
        [
          "ublituximab work via eliminating selected pathogenic cell populations",
          0.0474619026609469
        ],
        [
          "alemtuzumab and the anti-CD20",
          0.04581527489090142
        ],
        [
          "anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
          0.04424480059935291
        ],
        [
          "On the other hand, the anti-CD52 monoclonal antibody alemtuzumab and the anti-CD20",
          0.043252610129755
        ],
        [
          "ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations",
          0.03763055535537458
        ],
        [
          "ocrelizumab, ofatumumab, and ublituximab work via eliminating selected pathogenic cell populations",
          0.03708421065948506
        ],
        [
          "eliminating selected pathogenic cell populations",
          0.0364422406745602
        ],
        [
          "CD52 monoclonal antibody alemtuzumab",
          0.03322150328934765
        ],
        [
          "CD20 monoclonal antibodies rituximab, ocrelizumab, ofatumumab",
          0.031957522737603106
        ],
        [
          "anti-CD52",
          0.0273251392808246
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "640c842f201352f04a000025",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "liver palms",
          0.9712451091853908
        ],
        [
          "liver palms\"",
          0.016520749417340403
        ],
        [
          "\"liver palms",
          0.011048910146920034
        ],
        [
          "\"liver palms\"",
          0.00018794048396812382
        ],
        [
          "palms",
          8.619437718365335e-05
        ],
        [
          "liver",
          2.7020663269677332e-05
        ],
        [
          "palms\"",
          1.4661548286500028e-06
        ],
        [
          "\"liver",
          3.073877827063122e-07
        ],
        [
          "\"",
          8.931656799602199e-09
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64468b0757b1c7a315000070",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "PABPN1 gene",
          0.674763483369831
        ],
        [
          "PABPN1",
          0.28395177390338777
        ],
        [
          "poly[A]) binding protein nuclear 1 gene (11-18 repeats in OPMD instead of the normal 10 repeats)",
          0.2613692630235592
        ],
        [
          "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset intractable myopathy",
          0.25168524028193257
        ],
        [
          "abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
          0.1368463867377301
        ],
        [
          "Oculopharyngeal muscular dystrophy",
          0.10839679994741751
        ],
        [
          "polyadenosine (poly[A]) binding protein nuclear 1 gene",
          0.035929141885024024
        ],
        [
          "abnormal expansion of the alanine",
          0.020169381285180303
        ],
        [
          "abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat in the exon 1",
          0.017112300354062703
        ],
        [
          "polyadenosine (poly[A]) binding protein nuclear 1",
          0.0138335813074623
        ],
        [
          "A common cause of OPMD is the short expansion of a GCG or GCA trinucleotide repeat",
          0.013643581581155315
        ],
        [
          "the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
          0.012297636267480655
        ],
        [
          "It is caused by the abnormal expansion of the alanine-encoding (GCN)n trinucleotide repeat",
          0.010935741537745267
        ],
        [
          "abnormal expansion of",
          0.009023708167914766
        ],
        [
          "the short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene",
          0.0065509515803016775
        ],
        [
          "expansion of the alanine-encoding (GCN)n trinucleotide repeat",
          0.006502208348680465
        ],
        [
          "alanine-encoding (GCN)n trinucleotide repeat",
          0.004971220477852373
        ],
        [
          "poly[A]",
          0.004469820877349952
        ],
        [
          "short expansion of a GCG or GCA trinucleotide repeat in PABPN1 gene",
          0.003851439994414827
        ],
        [
          "PABPN",
          0.0032820033693870187
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63f0494cf36125a426000028",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "respiratory syncytial virus",
          3.520372616640294
        ],
        [
          "RSV",
          1.9924664435029509
        ],
        [
          "Respiratory Syncytial Virus Inhibitor",
          0.1671212697974952
        ],
        [
          "Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge",
          0.15164861678128858
        ],
        [
          "Human Virus Challenge",
          0.03912574889738286
        ],
        [
          "EDP-938, a Respiratory Syncytial Virus",
          0.023256540770812788
        ],
        [
          "respiratory",
          0.01683492687899726
        ],
        [
          "a Respiratory Syncytial Virus",
          0.01385070906551927
        ],
        [
          "RS",
          0.007511712931659416
        ],
        [
          "respiratory syncytial",
          0.006820336689853074
        ],
        [
          "respiratory syncyt",
          0.006297671257235887
        ],
        [
          "respiratory sync",
          0.005895136086275204
        ],
        [
          "EDP-938, a Respiratory Syncytial Virus Inhibitor",
          0.005265457815112837
        ],
        [
          "EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge",
          0.004999239641873386
        ],
        [
          "antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus",
          0.004897082609007809
        ],
        [
          "respiratory s",
          0.0042743666103964295
        ],
        [
          "Respiratory Syncytial Vir",
          0.003925945577566644
        ],
        [
          "Respiratory Syncytial Virus Inhibitor, in a Human Virus",
          0.0038240083318177905
        ],
        [
          "a Respiratory Syncytial Virus Inhibitor",
          0.0031359059377145636
        ],
        [
          "a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge",
          0.0029773565428655563
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "640ddbe9201352f04a000027",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "durvalumab",
          2.40059329262728
        ],
        [
          "IMFINZI",
          0.22392469480556348
        ],
        [
          "durvalumab (Imfinzi\u2122; AstraZeneca)",
          0.0010337908824228537
        ],
        [
          "IMFINZI\u00ae",
          0.0003827759929121526
        ],
        [
          "du",
          0.00023601000456071315
        ],
        [
          "durvalumab (Imfinzi\u00ae)",
          6.99419147999965e-05
        ],
        [
          "durvalumab (Imfinzi\u2122; AstraZeneca) is a fully human monoclonal antibody",
          5.812614722176965e-05
        ],
        [
          "IMFINZ",
          5.210839057290495e-05
        ],
        [
          "IMFINZI\u00ae, Astra-Zeneca",
          4.605729635948322e-05
        ],
        [
          "(IMFINZI\u00ae",
          1.148125318937709e-05
        ],
        [
          "durvalumab (IMFINZI\u00ae",
          5.90411487331909e-06
        ],
        [
          "I",
          1.8305088747715878e-06
        ],
        [
          "IMF",
          4.522446889961663e-07
        ],
        [
          "Imfinzi\u2122; AstraZeneca",
          1.0902729757020235e-07
        ],
        [
          "durvalum",
          8.873658486987157e-08
        ],
        [
          "blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80)",
          4.7389986239343603e-08
        ],
        [
          "programmed cell death ligand-1 binding to its receptors (PD-1 and CD80)",
          4.684453219312773e-08
        ],
        [
          "durva",
          4.513923274816604e-08
        ],
        [
          "CD80)",
          3.616974843411702e-08
        ],
        [
          "AstraZeneca",
          3.283552401047464e-08
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644e81fa57b1c7a315000079",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "tumor suppressor genes",
          0.9993756388375067
        ],
        [
          "tumour suppressor proteins",
          0.9935976132455097
        ],
        [
          "Tumor-suppressor genes (TSGs) or antioncogenes",
          0.29660487048570716
        ],
        [
          "Tumor-suppressor genes",
          0.20254722834206287
        ],
        [
          "antioncogenes",
          0.17690946723398254
        ],
        [
          "Tumor-suppressor genes (TSGs)",
          0.043393776937009736
        ],
        [
          "TSGs",
          0.03825829981377506
        ],
        [
          "loss of function of tumour suppressor proteins",
          0.004622975625686501
        ],
        [
          "Tumor-suppressor genes (TSGs) or antioncogene",
          0.004544543933960622
        ],
        [
          "antioncogene",
          0.002710585449462951
        ],
        [
          "(TSGs) or antioncogenes",
          0.0009149157471612304
        ],
        [
          "tumour suppressor proteins, drives oncogenic proliferation",
          0.0007783721141459494
        ],
        [
          "growth signalling networks, coupled to loss of function of tumour suppressor proteins",
          0.000504566934651014
        ],
        [
          "We now recognize that tumor suppressor genes",
          0.00027220445676302374
        ],
        [
          "tumor suppressor",
          0.00020892286297912986
        ],
        [
          "proteins",
          6.859801506519426e-05
        ],
        [
          "genes",
          6.334832716187481e-05
        ],
        [
          "tumor suppressor genes regulate diverse cellular activities",
          5.9232707893924046e-05
        ],
        [
          "growth signalling networks",
          4.243922674370911e-05
        ],
        [
          "genes (TSGs) or antioncogenes",
          4.083503800628793e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6415c7fb690f196b51000016",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "September 4, 2014",
          0.9917779023746011
        ],
        [
          "2014",
          0.006088896297781015
        ],
        [
          "On September 4, 2014",
          0.00200638049701535
        ],
        [
          "September 4",
          9.431368729349768e-05
        ],
        [
          "4, 2014",
          2.0160984356849663e-05
        ],
        [
          "September",
          1.0822184339372984e-05
        ],
        [
          ", 2014",
          4.977718991972519e-07
        ],
        [
          "September 4, 2014, the FDA approved pembrolizumab",
          4.133125377974677e-07
        ],
        [
          "On September 4",
          1.9079790176228897e-07
        ],
        [
          "On September",
          2.1893429508395724e-08
        ],
        [
          "2014, the FDA approved pembrolizumab",
          2.5374805943911153e-09
        ],
        [
          "4",
          1.6200865660451374e-09
        ],
        [
          "On",
          1.477221364515945e-09
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "64468e0d57b1c7a315000071",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "1 in 80,000 individuals worldwide",
          0.9434937830439122
        ],
        [
          "1 in 80,000",
          0.021935351835679486
        ],
        [
          "1 in 80,000 individuals",
          0.01807242559288472
        ],
        [
          "approximately 1 in 80,000 individuals worldwide",
          0.004312416815748298
        ],
        [
          "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600",
          0.0035166912107959334
        ],
        [
          "1",
          0.0018907412812003478
        ],
        [
          "late-onset rare muscle disease affecting approximately 1 in 80,000 individuals worldwide",
          0.00035569640638069647
        ],
        [
          "1 in 80,000 individuals worldwide. However, it can affect as much as 1:600 individuals",
          0.00026641903506592385
        ],
        [
          "1 in",
          0.00018384254101533947
        ],
        [
          "worldwide",
          0.00015242164864285606
        ],
        [
          "80,000 individuals worldwide",
          0.00014761903749247187
        ],
        [
          "approximately 1 in 80,000",
          0.00010082203638835756
        ],
        [
          "approximately 1 in 80,000 individuals",
          8.30667665785022e-05
        ],
        [
          "1:600 individuals in some populations due to a strong founder effect",
          6.938784991470916e-05
        ],
        [
          "1:600",
          4.650091886199711e-05
        ],
        [
          "1 in 80",
          2.5825936274206508e-05
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63f04716f36125a426000025",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "angioedema",
          1.9968252034055567
        ],
        [
          "HAE",
          0.9995066078134717
        ],
        [
          "Hereditary angioedema",
          0.0031426040301799235
        ],
        [
          "Given the requirement of lifelong management for HAE",
          0.000145065496513213
        ],
        [
          "H",
          0.00012951015744925906
        ],
        [
          "HA",
          1.8849808030763626e-05
        ],
        [
          "prophylaxis. Given the requirement of lifelong management for HAE",
          1.5075561021477295e-05
        ],
        [
          "have shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
          1.3466276571853533e-05
        ],
        [
          "an",
          1.1919064829155569e-05
        ],
        [
          "the requirement of lifelong management for HAE",
          7.515410522590421e-06
        ],
        [
          "as long-term prophylaxis. Given the requirement of lifelong management for HAE",
          6.84370756510722e-06
        ],
        [
          "shown promise as long-term prophylaxis. Given the requirement of lifelong management for HAE",
          6.3114024402379805e-06
        ],
        [
          "Among patients with hereditary angioedema",
          5.904469434057566e-06
        ],
        [
          "CONCLUSIONS: Among patients with hereditary angioedema",
          4.794924474579633e-06
        ],
        [
          "BACKGROUND: Hereditary angioedema",
          4.72525442038579e-06
        ],
        [
          "HAE, further research is needed to determine how best to individualize optimal treatments",
          3.375516126950134e-06
        ],
        [
          "HAE, further research is needed",
          3.3600034211968026e-06
        ],
        [
          "patients with hereditary angioedema",
          5.768186053519159e-07
        ],
        [
          "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema",
          8.135982039094842e-08
        ],
        [
          "angioedema, donidalorsen treatment resulted in a significantly lower rate of angioedema attacks",
          5.298336330882364e-08
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644ec7fe57b1c7a315000082",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "The lac operon",
          0.6280655559066745
        ],
        [
          "colilac operon",
          0.453864259540419
        ],
        [
          "colilac operon. Most studies of lac operon regulation have focused on a few closely related strains",
          0.4526841468202178
        ],
        [
          "lac operon",
          0.09505886780693865
        ],
        [
          "colilac",
          0.06398952363656615
        ],
        [
          "The lac",
          0.010708470377200244
        ],
        [
          "Escherichia colilac operon",
          0.010000579801905841
        ],
        [
          "colilac operon. Most studies of lac operon",
          0.0070977048433548155
        ],
        [
          "The lac operon is one of the best known gene regulatory circuits",
          0.006183898874793251
        ],
        [
          "The",
          0.002669685637655743
        ],
        [
          "The lac operon is one of the best known gene regulatory",
          0.0020392402179353255
        ],
        [
          "lac",
          0.0016207465294467661
        ],
        [
          "Escherichia colilac",
          0.001029761262401283
        ],
        [
          "lac operon is one of the best known gene regulatory circuits",
          0.0009359443773697341
        ],
        [
          "the Escherichia colilac operon",
          0.0006795022539457208
        ],
        [
          "lac operon regulation have focused on a few closely related strains",
          0.0003851958940097671
        ],
        [
          "Most studies of lac operon regulation have focused on a few closely related strains",
          0.00030958459389856586
        ],
        [
          "lac operon is one of the best known gene regulatory",
          0.0003086427276265268
        ],
        [
          "lactose to control the Escherichia colilac operon",
          0.0002206275027566953
        ],
        [
          "cis- and trans-acting regulators",
          0.00021234229592833505
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "63fa16d8201352f04a000002",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "colorectal cancer",
          0.9980108801337778
        ],
        [
          "CRC",
          0.997102427559721
        ],
        [
          "CR",
          0.002888885547120751
        ],
        [
          "colorectal",
          0.001636259065259171
        ],
        [
          "cancer",
          0.00021580095702301952
        ],
        [
          "color",
          0.0001337852241528979
        ],
        [
          "CRC metastasis",
          3.5712103724182705e-06
        ],
        [
          "we found that changes in the pattern of microexon splicing were associated with CRC",
          3.3813317714901452e-06
        ],
        [
          "RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer",
          9.522243869177409e-07
        ],
        [
          "colorec",
          7.186132091092108e-07
        ],
        [
          "PTBP1 is associated with metastasis in colorectal cancer",
          2.8759951457576847e-07
        ],
        [
          "metastasis in colorectal cancer",
          2.4614697397888373e-07
        ],
        [
          "Finally, we found that changes in the pattern of microexon splicing were associated with CRC",
          2.0650765646988026e-07
        ],
        [
          "in colorectal cancer",
          1.614845598172933e-07
        ],
        [
          "CRC metastasis. Our data thus suggest that altered expression of RBFOX2 and PTBP1",
          1.534647033957799e-07
        ],
        [
          "CRC metastasis. Our data thus suggest that altered expression of RBFOX2",
          1.3051654233206093e-07
        ],
        [
          "associated with metastasis in colorectal cancer",
          9.805627461802886e-08
        ],
        [
          "changes in the pattern of microexon splicing were associated with CRC",
          9.603598639115168e-08
        ],
        [
          "CRC metastasis. Our data",
          9.340704450210343e-08
        ],
        [
          "CRC metastasis. Our data thus suggest",
          8.315816390931989e-08
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6451060c57b1c7a315000096",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "androgen receptor (AR) gene",
          1.2153286652218456
        ],
        [
          "androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons to cause SBMA",
          0.317742492060714
        ],
        [
          "Kennedy",
          0.29340711781396495
        ],
        [
          "Kennedy's disease",
          0.26771365043156015
        ],
        [
          "androgen receptor",
          0.17960511102188567
        ],
        [
          "and",
          0.0958382715414523
        ],
        [
          "androgen receptor (AR)",
          0.06635081743081578
        ],
        [
          "androgen receptor encoding gene (AR)",
          0.04654552047049031
        ],
        [
          "a CAG trinucleotide repeat expansion",
          0.04399426631188174
        ],
        [
          "androgen",
          0.014505225647462636
        ],
        [
          "androgen receptor (AR) gene, and mutant AR is presumed to act in motoneurons",
          0.007823782632940248
        ],
        [
          "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor encoding gene",
          0.007070540251947533
        ],
        [
          "Kennedy's disease is nearly exclusively caused by mutations in the androgen",
          0.0024810931690631335
        ],
        [
          "a CAG trinucleotide repeat expansion in the androgen receptor (AR) gene",
          0.0022517749390086627
        ],
        [
          "Kennedy's disease is nearly exclusively caused by mutations",
          0.001210581495266285
        ],
        [
          "Kennedy's disease is nearly exclusively caused by mutations in the androgen receptor",
          0.001044550816506684
        ],
        [
          "androgen receptor encoding gene",
          0.0008773143529554327
        ],
        [
          "androgen receptor (AR) gene, and",
          0.0008486810051392151
        ],
        [
          "Kennedy's disease is nearly exclusively caused by mutations in the and",
          0.000783560321593151
        ],
        [
          "mutations in the androgen receptor encoding gene (AR)",
          0.0003933549473134924
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "61f7c904882a024a10000027",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "asthma",
          8.00933669711072
        ],
        [
          "eosinophilic asthma",
          0.9622673910051831
        ],
        [
          "Severe Asthma",
          0.025820188889046802
        ],
        [
          "as",
          0.002253170855900601
        ],
        [
          "Patients With Severe Asthma",
          0.00010797219699939274
        ],
        [
          "asth",
          3.723271048410302e-05
        ],
        [
          "asthma that is effective also in nontype 2 asthma",
          3.6231685708497944e-05
        ],
        [
          "With Severe Asthma",
          2.1031398954520484e-05
        ],
        [
          "Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma",
          1.8518091512034984e-05
        ],
        [
          "severe, uncontrolled asthma",
          1.55424832828395e-05
        ],
        [
          "In severe, uncontrolled asthma",
          1.3297160365775145e-05
        ],
        [
          "Phase 3 Dose Selection for Patients With Severe Asthma",
          8.25925276315213e-06
        ],
        [
          "thymic stromal lymphopoietin, an epithelial cytokine involved in asthma",
          7.462186282637711e-06
        ],
        [
          "e",
          5.864118398399413e-06
        ],
        [
          "Tezepelumab in adults and adolescents with severe, uncontrolled asthma",
          5.139788972221907e-06
        ],
        [
          "Dose Selection for Patients With Severe Asthma",
          4.8004636470405195e-06
        ],
        [
          "TSLP monoclonal antibody, is a promising alternative treatment for asthma",
          4.465591220736582e-06
        ],
        [
          "asthma pathogenesis",
          3.837781416090608e-06
        ],
        [
          "asthma, tezepelumab reduced exacerbations and improved asthma control at 1 y",
          3.825975984694522e-06
        ],
        [
          "Severe As",
          2.7454801011284898e-06
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644ef78f57b1c7a315000084",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "chromatin fibres, and tethering of chromosomal regions to nuclear structures",
          0.18829474805001234
        ],
        [
          "nucleoprotein complex",
          0.15933880986982327
        ],
        [
          "DNA in eukaryotes is packed into chromatin",
          0.15882798890553262
        ],
        [
          "Inside the cell nucleus, chromatin is folded into higher-order structures",
          0.11904198077287996
        ],
        [
          "nucleosome",
          0.10740666300472092
        ],
        [
          "nucleosome consisting of DNA wrapped around a histone octamer",
          0.08417320428011765
        ],
        [
          "chromatin fibres",
          0.07956388333333225
        ],
        [
          "Inside the cell nucleus, chromatin is folded into higher-order structures through various mechanisms",
          0.04850309471157523
        ],
        [
          "higher-order structures",
          0.046291621436966836
        ],
        [
          "nuclear structures",
          0.03782163181890685
        ],
        [
          "chromatin is folded into higher-order structures",
          0.03546451118808071
        ],
        [
          "Inside the cell nucleus",
          0.03263287239438381
        ],
        [
          "looping of chromatin fibres, and tethering of chromosomal regions to nuclear structures",
          0.032139725456796796
        ],
        [
          "the nucleosome",
          0.024889327607088896
        ],
        [
          "chromatin is the nucleosome consisting of DNA wrapped around a histone octamer",
          0.022499637755231516
        ],
        [
          "chromatin",
          0.02027691696442392
        ],
        [
          "higher-order structures through various mechanisms",
          0.018861303250601726
        ],
        [
          "chromatin is folded into higher-order structures through various mechanisms",
          0.014449848145059415
        ],
        [
          "the nucleosome consisting of DNA wrapped around a histone octamer",
          0.012362174038869843
        ],
        [
          "histone octamer",
          0.012320039639867095
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "644298cc57b1c7a315000062",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Facial-scapular-humeral myodystrophy Landouzy-Dejerine",
          0.9531427907474816
        ],
        [
          "SMCHD1",
          0.42720253919055046
        ],
        [
          "Landouzy-Dejerine",
          0.03942775374010723
        ],
        [
          "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin -",
          0.036018010069854695
        ],
        [
          "FSHD2 is caused by the mutations in the protein regulating the methylation status of chromatin",
          0.018114767161561456
        ],
        [
          "mutations in the protein regulating the methylation status of chromatin - SMCHD1",
          0.014021804310656204
        ],
        [
          "FSHD2 is caused by the mutations",
          0.003154604793338243
        ],
        [
          "the mutations in the protein regulating the methylation status of chromatin - SMCHD1",
          0.003022525391567827
        ],
        [
          "FSHD2",
          0.001962437047285658
        ],
        [
          "the protein regulating the methylation status of chromatin - SMCHD1",
          0.0016395084331709514
        ],
        [
          "ectopic expression of the transcription factor DUX4 in skeletal muscle",
          0.0012976921565110665
        ],
        [
          "autosomal dominant",
          0.0012599493255337584
        ],
        [
          "FSHD2 is caused by the mutations in",
          0.0012085923941571137
        ],
        [
          "mutations in the protein regulating the methylation status of chromatin -",
          0.001032923864033464
        ],
        [
          "SMCHD",
          0.0009868409290220476
        ],
        [
          "FSHD2 is caused by the mutations in the protein regulating the methylation status",
          0.0008955392374530213
        ],
        [
          "Facial-scapular-humeral myodystrophy Landouzy-Dejerine (FSHD)",
          0.0008471408720550033
        ],
        [
          "Facial-scapular-humeral myodystrophy",
          0.000840376842580323
        ],
        [
          "by the mutations in the protein regulating the methylation status of chromatin - SMCHD1",
          0.0006707484467284657
        ],
        [
          "Landouzy-Dejerine (FSHD) is an autosomal dominant",
          0.0006362306879524071
        ]
      ]
    },
    {
      "type": "factoid",
      "id": "6442933f57b1c7a315000060",
      "ideal_answer": [
        "Dummy"
      ],
      "exact_answer": [
        [
          "Facial-scapular-humeral myodystrophy Landouzy-Dejerine",
          0.967689970952753
        ],
        [
          "partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          0.3945411492274824
        ],
        [
          "deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          0.19144286352497072
        ],
        [
          "In FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          0.04714072781354328
        ],
        [
          "FSHD1, partial deletion of the D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          0.040857191465242956
        ],
        [
          "different genetic causes but are phenotypically indistinguishable",
          0.03356893704858471
        ],
        [
          "D4Z4 repeats on the 4th chromosome affects the expression of DUX4",
          0.030096654536199037
        ],
        [
          "partial deletion of the D4Z4 repeats",
          0.028229328036561314
        ],
        [
          "Landouzy-Dejerine",
          0.027641770224469245
        ],
        [
          "which have different genetic causes but are phenotypically indistinguishable",
          0.027206649091622345
        ],
        [
          "DUX4",
          0.02607670634341077
        ],
        [
          "have different genetic causes but are phenotypically indistinguishable",
          0.025041540744147134
        ],
        [
          "partial deletion of the D4Z4",
          0.02501879203835098
        ],
        [
          "genetic causes but are phenotypically indistinguishable",
          0.023642156756338475
        ],
        [
          "partial deletion of the D4Z4 repeats on the 4th chromosome",
          0.01967833446508967
        ],
        [
          "FSHD2 (MIM: 158901)",
          0.017336961825311078
        ],
        [
          "partial deletion",
          0.016219917210629098
        ],
        [
          "deletion of the D4Z4 repeats",
          0.013697692636843447
        ],
        [
          "deletion of the D4Z4",
          0.01213984700743103
        ],
        [
          "FSHD1 (MIM:158900) and FSHD2 (MIM: 158901)",
          0.010532360327388827
        ]
      ]
    }
  ]
}